Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (<b>A</b>, <b>C</b>, and <b>E</b>) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best...
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Eará dahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Almmustuhtton: |
2025
|
| Fáttát: | |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Lasit vuosttaš kommeantta. Visot kommeanttat leat almmolaččat.!